News Quantified

CLSD – clearside biomedical, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.

All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy [Yahoo! Finance]

Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]

Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.

-2.7%

BEAT

-0.5%

BEAT

-7.4%

MISS

-5.2%

BEAT

Chardan Capital

Chardan Capital

Needham & Company LLC

Form 10-Q Clearside Biomedical, For: Sep 30

Form 8-K Clearside Biomedical, For: Nov 12

Form 4 Clearside Biomedical, For: Nov 01 Filed by: Chong Ngai Hang Victor

Form 8-K Clearside Biomedical, For: Oct 09

Top News Gainers

1/6 Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference 29.2%

8/7 Q2/2019 6/30/2019 EPS -0.150 ZacksConsensus -0.370 ActVsEst 0.220 - Beat 28.0%

10/22 Clearside Biomedical Inc (NASDAQ: CLSD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $1.00 price target on the stock. 19.0%

9/3 Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference 16.0%

11/26 Form 4 Clearside Biomedical, For: Nov 22 Filed by: Thorp Clay 12.5%

4/8 Clearside Biomedical to Present at the Needham Virtual Healthcare Conference 11.7%

10/3 Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting 9.2%

1/27 Clearside Biomedical Inc (NASDAQ: CLSD) had its price target raised by analysts at Wedbush from $3.00 to $5.00. They now have an "outperform" rating on the stock. 8.5%

3/20 Clearside Biomedical Inc (NASDAQ: CLSD) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. 7.9%

10/21 Clearside Biomedical Inc (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock. 7.3%

Top News Decliners

8/22 Form 8-K Clearside Biomedical, For: Aug 22 -40.1%

3/11 Form 8-K Clearside Biomedical, For: Mar 11 -36.0%

3/13 Form 424B5 Clearside Biomedical, -29.5%

4/28 Form 8-K Clearside Biomedical, For: Apr 27 -17.4%

2/27 Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020 -14.3%

8/26 Clearside Biomedical Inc (NASDAQ: CLSD) was given a new $1.00 price target on by analysts at Laidlaw. They now have a "hold" rating on the stock. -10.6%

8/22 Clearside Biomedical Inc (NASDAQ: CLSD) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $3.00 price target on the stock, down previously from $4.00. -9.6%

9/4 Form 8-K Clearside Biomedical, For: Aug 29 -9.4%

6/4 Form 4 Clearside Biomedical, For: May 31 Filed by: Raymond Brion S. -8.8%

3/16 Form 8-K Clearside Biomedical, For: Mar 11 -8.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day